Table of Contents
Overview
New York, NY – June 30, 2025 – The Global Genetic Engineering Market size is expected to be worth around US$ 3.1 Billion by 2034 from US$ 1.7 Billion in 2024, growing at a CAGR of 6.2% during the forecast period 2025 to 2034. In 2024, North America led the market, achieving over 42.1% share with a revenue of US$ 0.7 Billion.
The global genetic engineering market is witnessing significant momentum, supported by rapid advancements in gene editing technologies and growing demand across healthcare, agriculture, and industrial sectors. Genetic engineering enables precise modification of DNA to alter genetic traits, offering revolutionary potential in disease treatment, crop enhancement, and sustainable manufacturing.
In the healthcare sector, genetic engineering plays a vital role in gene therapy, precision medicine, and vaccine development. Tools like CRISPR-Cas9 are enabling targeted genetic corrections, showing promising results in treating rare genetic disorders, cancers, and infectious diseases. According to the U.S. National Institutes of Health (NIH), there are over 1,200 gene therapy clinical trials underway globally, indicating growing investment and research in this field.
Agriculture is another key area where genetically engineered crops are improving yield, pest resistance, and climate resilience. The Food and Agriculture Organization (FAO) highlights the contribution of biotech crops in addressing global food security and reducing chemical pesticide use.
Moreover, genetic engineering is being integrated into industrial biotechnology to produce biofuels, enzymes, and biodegradable materials more efficiently. This trend supports the global shift toward sustainable and eco-friendly production systems.
The genetic engineering market is expected to continue expanding as regulatory frameworks evolve, ethical concerns are addressed, and cross-sector collaborations increase. This growth trajectory reflects the transformative role of biotechnology in shaping future innovations.
Key Takeaways
- In 2024, the global genetic engineering market generated revenue of approximately US$ 1.7 billion and is projected to reach US$ 3.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 6.2% during the forecast period.
- By product type, the market is segmented into genetic markers and biochemical. Among these, genetic markers dominated in 2023, accounting for 61.5% of the total market share.
- In terms of technology, the market is classified into artificial selection and gene splicing. Gene splicing held the leading share, representing 54.7% of the market.
- Based on application, the market is divided into agriculture and medical industry. The medical industry emerged as the dominant application segment, capturing 52.6% of total revenue.
- Regarding devices, the market includes PCR, gel assemblies, and gene guns. The PCR segment led the market, with a revenue share of 53.2% in 2023.
- Regionally, North America accounted for the largest market share, holding 42.1% of the global revenue in 2023, supported by strong research infrastructure and high adoption of gene editing technologies.
Segmentation Analysis
- Product Type Analysis: The genetic markers segment held 61.5% market share due to its vital role in identifying gene-trait associations and enabling precision breeding. It is widely used in disease mapping, crop improvement, and personalized medicine. Increasing use in oncology and pharmacogenomics, supported by next-generation sequencing and reduced genotyping costs, is enhancing adoption. Investments in genomics and regulatory support for biomarker-based diagnostics are expected to accelerate market expansion across medical, forensic, and agricultural fields.
- Technology Analysis: Gene splicing accounted for 54.7% of the market share, driven by its application in gene editing, therapeutic protein production, and transgenic organism development. CRISPR-Cas9 advancements have improved precision, fueling widespread use in biotech and agriculture. Growing demand for gene therapies, coupled with favorable regulatory developments and industry-academic collaborations, supports continued growth. This technology plays a key role in developing disease-resistant crops and novel treatments, positioning gene splicing as a major force in genetic engineering innovation.
- Application Analysis: The medical industry led the application segment with a 52.6% revenue share, supported by rising demand for personalized medicine, gene therapies, and advanced diagnostics. Hospitals and research centers increasingly utilize genetic engineering for cancer, rare diseases, and cardiovascular conditions. Strong biotech investments, regulatory approvals, and growing clinician adoption are reinforcing growth. Integration of AI and bioinformatics improves genomic analysis, while public and private funding ensures innovation, securing the medical sector’s leadership in genomic technology applications.
- Device Analysis: PCR devices captured 53.2% of the market due to their widespread use in amplifying DNA for diagnostics, sequencing, and cloning. Their speed, precision, and reliability make them essential in research labs, hospitals, and educational institutions. Digital and real-time PCR innovations are enhancing sensitivity and broadening clinical and agricultural uses. The demand for rapid disease testing, including for COVID-19, has further driven adoption. Miniaturized and cost-effective PCR systems are expanding usage in developing regions and academic training.
Market Segments
By Product Type
- Genetic Markers
- Biochemical
By Technology
- Artificial Selection
- Gene Splicing
By Application
- Agriculture
- Medical Industry
By Device
- PCR
- Gel Assemblies
- Gene Gun
Regional Analysis
North America held the largest revenue share of 42.1% in the genetic engineering market, primarily due to robust investment in research and development. Significant funding from organizations such as the National Institutes of Health (NIH) supports advancements in gene editing and therapy.
The U.S. Food and Drug Administration (FDA) has increasingly approved gene therapies between 2022 and 2024, reflecting regulatory confidence and accelerating clinical applications. The region’s focus on developing personalized medicines for genetic disorders and cancer continues to drive demand for advanced genetic technologies.
Asia Pacific is projected to record the highest compound annual growth rate (CAGR) over the forecast period. This growth is fueled by strong government initiatives in biotechnology and genomics. India’s Department of Biotechnology (DBT) supports numerous projects, including the DST-ICGEB Bio-Foundry, to advance genetic engineering.
Singapore’s National Precision Medicine Program aims to sequence large genomic datasets, enhancing diagnostics and therapeutic strategies. Additionally, the rising burden of genetic disorders and increased use of genetic tools in agriculture to improve crop productivity are expected to further accelerate market expansion in the region.
Emerging Trends
- Expansion of Precision Gene-Editing Tools: The use of CRISPR-Cas systems has been broadly adopted for precise genome modifications. Base editing and prime editing approaches are being refined to introduce single-base changes without creating double-strand breaks. These next-generation editors enable more accurate corrections of pathogenic mutations and are being applied across human cells and model organisms.
- Integration of Multi-Omics and Computational Design: Multi-omics methods combining genomics, transcriptomics, proteomics, metabolomics, and epigenomics are now routinely used to guide genetic engineering projects. These approaches allow comprehensive assessment of intended and unintended effects, improving the safety and efficacy of engineered organisms, especially in crop improvement programs.
- Strengthened Governance and Ethical Frameworks: New guidelines have been issued to ensure responsible development and oversight of human genome editing. Recommendations cover areas such as registry creation, international research standards, and ethical review processes, with a focus on both somatic and heritable editing to safeguard public health and equity.
- Advancements in Agricultural Gene Editing: Gene editing is increasingly used to develop disease-resistant and stress-tolerant crops. Recent work has produced wheat varieties resistant to powdery mildew, rice strains with enhanced bacterial-blight tolerance, and virus-resistant tomato lines. These innovations promise to improve yields and reduce pesticide use in major food crops.
Use Cases
- Approved Therapeutic Products: As of May 15, 2025, 45 cellular and gene therapy products had been licensed by the U.S. FDA. These products encompass treatments ranging from cancer immunotherapies to enzyme-replacement strategies for rare diseases.
- Treatment of Sickle Cell Disease: In late 2023, two landmark cell-based gene therapies Casgevy and Lyfgenia were approved for patients aged 12 years and older with sickle cell disease. These approvals mark the first FDA-licensed genome-editing treatments for this condition.
- Regulatory Exemptions for Engineered Plants: Since 2020, at least 99 genetically engineered plant varieties have been exempted from certain USDA-APHIS permitting requirements under an updated regulatory rule. This change has accelerated field trials and commercialization of new traits in row and specialty crops.
- Vector Control for Malaria Reduction: Genetic engineering of mosquitoes is being evaluated as a public health tool to curb malaria transmission. In 2023, the WHO reported an estimated 263 million malaria cases and 597 000 deaths worldwide, underscoring the urgent need for innovative control measures such as gene-drive technologies in vector populations.
Conclusion
The global genetic engineering market is positioned for sustained growth, driven by technological innovation, expanding therapeutic applications, and supportive regulatory environments. Key advancements in CRISPR, PCR, and multi-omics are enhancing precision and efficiency across healthcare, agriculture, and industrial domains. North America remains the market leader, while Asia Pacific is expected to grow rapidly due to government-backed genomic initiatives.
The increasing approval of gene therapies and genetically engineered crops highlights the market’s maturity and potential. As ethical frameworks evolve and global collaborations strengthen, genetic engineering is set to play a transformative role in addressing critical health, food, and environmental challenges.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
